Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial funding. To avoid having to wholly finance all its phase III studies the company will accept funds from external parties, enabling Eisai to start late-stage trials earlier than would otherwise be possible. Eisai said the new partnership approach would allow it “to conduct pivotal phase III studies for promising new drug candidates in order to push forward with numerous development programmes simultaneously and as quickly as possible”.
